文献速递心律失常瓣膜病与结构性心脏病

主动固定电极连接体外起搏器桥接治疗感染性心内膜炎拔除导线后患者

[Feasibility and safety of bridge therapy with active fixed electrodes connected to external permanent pacemakers for patients with infective endocarditis after lead removal and before permanent pacemaker implantation].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2022-01-01

该回顾性队列研究纳入44例因感染性心内膜炎拔除起搏器导线后需临时起搏过渡的患者,比较主动固定电极连接体外永久起搏器(AFLEP)与临时起搏器的安全性与可行性。结果显示AFLEP组无电极脱位、感知异常、死亡及深静脉血栓,起搏功能异常经调整输出电压改善,过渡时间较长但再感染率更低。

要点

  • AFLEP桥接治疗在感染性心内膜炎拔除导线后患者中安全可行。
  • AFLEP组无电极脱位、感知异常、死亡及深静脉血栓发生。
  • AFLEP组过渡时间较长但新植入起搏器再感染率更低。

核心结论

  • 应用AFLEP对感染性心内膜炎患者拔除导线后进行过渡治疗安全可行,相比临时起搏器感知和起搏功能障碍发生率更低、更稳定。

研究设计与样本

  • 回顾性队列研究,纳入2015年1月至2020年1月因感染性心内膜炎拔除导线后需临时起搏过渡的44例患者,AFLEP组24例,临时起搏器组20例。

主要发现

  • AFLEP组年龄57.5(45.5,66.0)岁,较临时起搏器组67.0(57.3,71.8)岁年轻(P=0.023)。
  • 临时起搏器组发生电极脱位2例(10.0%)、感知功能异常2例(10.0%)、起搏功能异常2例(10.0%)、死亡2例(10.0%),AFLEP组无上述并发症。
  • AFLEP组无下肢深静脉血栓,临时起搏器组4例(20.0%),两组比较差异有统计学意义(P=0.036)。
  • AFLEP组过渡治疗时间19.5(16.0,25.8)d,长于临时起搏器组14.0(12.0,16.8)d(P=0.001)。
  • 随访期间AFLEP组无新植入起搏器再感染,临时起搏器组2例(10.0%)发生再感染。

临床怎么用

  • 对于感染性心内膜炎拔除导线后依赖起搏器的患者,可考虑使用AFLEP进行桥接过渡治疗。
  • AFLEP可能降低电极脱位、感知和起搏功能障碍及深静脉血栓风险,但需注意过渡时间可能较长。

局限性

  • 本研究为单中心回顾性队列研究,样本量44例,结果需更大规模前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To analyze the feasibility and safety of bridge therapy with active fixed electrodes connected to external permanent pacemakers (AFLEP) for patients with infective endocarditis after lead removal and before permanent pacemaker implantation. Methods: A total of 44 pacemaker-dependent patients, who underwent lead removal due to infective endocarditis in our center from January 2015 to January 2020, were included. According to AFLEP or temporary pacemaker option during the transition period, patients were divided into AFLEP group or temporary pacemaker group. Information including age, sex, comorbidities, indications and types of cardial implantable electionic device (CIED) implantation, lead age, duration of temporary pacemaker or AFLEP use, and perioperative complications were collected through Haitai Medical Record System. The incidence of pacemaker perception, abnormal pacing function, lead perforation, lead dislocation, lead vegetation, cardiac tamponade, pulmonary embolism, death and newly infection of implanted pacemaker were compared between the two groups. Pneumothorax, hematoma and the incidence of deep vein thrombosis were also analyzed. Results: Among the 44 patients, 24 were in the AFLEP group and 20 in the temporary pacemaker group. Age was younger in the AFLEP group than in the temporary pacemaker group (57.5(45.5, 66.0) years vs. 67.0(57.3, 71.8) years, P=0.023). Male, prevalence of hypertension, diabetes mellitus, chronic renal dysfunction and old myocardial infarction were similar between the two groups (all P>0.05). Lead duration was 11.0(8.0,13.0) years in the AFLEP group and 8.5(7.0,13.0) years in the temporary pacemaker group(P=0.292). Lead vegetation diameter was (8.2±2.4)mm in the AFLEP group and (9.1±3.0)mm in the temporary pacemaker group. Lead removal was successful in all patients. The follow-up time in the AFLEP group was 23.0(20.5, 25.5) months, and the temporary pacemaker group was 17.0(14.5, 18.5) months. In the temporary pacemaker group, there were 2 cases (10.0%) of lead dislocation, 2 cases (10.0%) of sensory dysfunction, 2 cases (10.0%) of pacing dysfunction, and 2 cases (10.0%) of death. In the AFLEP group, there were 2 cases of abnormal pacing function, which improved after adjusting the output voltage of the pacemaker, there was no lead dislocation, abnormal perception and death. Femoral vein access was used in 8 patients (40.0%) in the temporary pacemaker group, and 4 patients developed lower extremity deep venous thrombosis. There was no deep venous thrombosis in the AFLEP group. The transition treatment time was significantly longer in the AFLEP group than in the temporary pacemaker group (19.5(16.0, 25.8) days vs. 14.0(12.0, 16.8) days, P=0.001). During the follow-up period, there were no reinfections with newly implanted pacemakers in the AFLEP group, and reinfection occurred in 2 patients (10.0%) in the temporary pacemaker group. Conclusions: Bridge therapy with AFLEP for patients with infective endocarditis after lead removal and before permanent pacemaker implantation is feasible and safe. Compared with temporary pacemaker, AFLEP is safer in the implantation process and more stable with lower lead dislocation rate, less sensory and pacing dysfunction. 目的: 探讨在感染性心内膜炎患者中应用主动固定电极连接体外永久起搏器(AFLEP)进行临时起搏过渡治疗的安全性。 方法: 该研究为回顾性队列研究。入选2015年1月至2020年1月于北京大学人民医院电生理室就诊的因感染性心内膜炎拔除电极导线后需要进行临时起搏器过渡治疗的患者。根据过渡治疗期间使用的是临时起搏器还是AFLEP,分为临时起搏器组和AFLEP组。通过电子病历系统收集入选患者的年龄、性别、合并症、电极导线年限、赘生物大小等基线临床资料,以及临时起搏器和主动固定电极连接体外永久起搏器使用的时间和围术期相关并发症。观察指标包括患者的感知、起搏功能异常,电极导线穿孔,电极导线脱位,电极导线赘生物,心脏填塞,肺栓塞,死亡和新植入起搏器再发感染,气胸,血肿,和深静脉血栓等的发生情况。 结果: 共入选患者44例,其中AFLEP组24例,临时起搏器组20例。AFLEP组患者57.5(45.5,66.0)岁,较临时起搏器组[67.0(57.3,71.8)岁]年轻(P=0.023)。两组患者中男性占比以及合并高血压、糖尿病、慢性肾功能不全和既往心肌梗死患者占比差异均无统计学意义(P均>0.05)。AFLEP组电极导线植入年限为11.0(8.0,13.0)年,长于临时起搏器组的8.5(7.0,13.0)年(P=0.292)。AFLEP组患者电极导线赘生物直径为(8.2±2.4)mm,临时起搏器组为(9.1±3.0)mm。两组所有患者起搏器及电极导线均临床拔除成功。两组均无患者发生气胸、血肿、肺栓塞、心脏填塞、电极穿孔和电极导线或瓣膜赘生物等并发症。AFLEP组无患者发生下肢深静脉血栓,临时起搏器组有4例(20.0%),两组比较差异有统计学意义(P=0.036)。临时起搏器组患者发生电极脱位2例(10.0%)、感知功能异常2例(10.0%)、起搏功能异常2例(10.0%)、死亡2例(10.0%),AFLEP组无患者发生上述并发症。AFLEP组过渡治疗时间为19.5(16.0,25.8)d,长于临时起搏器组的14.0(12.0,16.8)d(P=0.001)。AFLEP组随访23.0(20.5,25.5)个月,临时起搏器组随访17.0(14.5,18.5)个月,随访期间AFLEP组无患者发生新植入起搏器再感染,临时起搏器组有2例(10.0%)患者发生再感染。 结论: 应用AFLEP对感染性心内膜炎患者进行过渡治疗,植入过程安全,相较于临时起搏器其感知和起搏功能障碍发生率更低、更加稳定,安全可行。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. He JS, Duan JB, Li SC, et al. [Feasibility and safety of bridge therapy with active fixed electrodes connected to external permanent pacemakers for patients with infective endocarditis after lead removal and before permanent pacemaker implantation]. Zhonghua Xin Xue Guan Bing Za Zhi. 2022. PMID: 36517443. doi:10.3760/cma.j.cn112148-20220523-00408

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。